# Contact Script TB-500 | TB-500 Editorial

> Contact Script TB-500, the independent editorial project covering the TB-500 and thymosin beta-4 research record. Editorial correspondence only — not a clinic, pharmacy, or vendor.

Editorial correspondence about the TB-500 and thymosin beta-4 record — corrections, citations, and questions about the sources.

## Editorial correspondence

Use the form below to reach Script TB-500 about the editorial content of this site. We welcome corrections, additional citations, and questions about the studies we read from. If you believe a claim is miscited or a source has been superseded, point us to the primary reference and we will review it.

Script TB-500 is an editorial publisher, not a clinic, pharmacy, compounding facility, or vendor. We cannot provide medical advice, we cannot recommend doses or protocols, and we cannot help anyone obtain TB-500 or any other substance. Messages asking for sourcing, pricing, dosing, or treatment guidance will not receive that information, because providing it is outside what this project does.

## What to expect

We read messages about the research record and the accuracy of what is published here. We do not respond to requests for product, supply, or clinical guidance. For the regulatory picture — FDA 503A status, compounding, and WADA standing — the legal-status page already sets out what we can responsibly say, drawn from the FDA's own published pages.

This is a reading of the literature, maintained so that the published evidence on TB-500 is easier to find, check, and weigh.

---

A reading of the TB-500 and thymosin beta-4 record graded by heat — each finding rated for how hot its data run, the parent-protein substitutions flagged cell by cell, and the human-evidence band left cold and labeled; no clinic behind the matrix and nothing here prescribed or sold.